Immunological Monitoring & Cellular Products

核心B：免疫监测和细胞产品实验室/组织微阵列核心（IMCPL/TMA） 该实验室是匹兹堡大学癌症研究所（UPCI）的一个专门设施， 致力于在治疗之前、期间和之后对免疫应答进行最先进的评价 对癌症患者的干预。除了产生用于人类治疗的细胞产物外， 提供专业的形态学服务。作为皮肤孢子的核心B，IMCPL将承担 负责支持项目提出的基于生物治疗的临床试验。核心B，功能正常 作为GMP设施，将培养和表征用于患者治疗的树突状细胞（DC）并制备疫苗 通过用肽或蛋白质脉冲这些DC或用AdV感染DC，如临床方案中所规定的 与之相关的是，核心B将负责基于DC的 疫苗。它还将采购和处理在临床过程中采集的所有体液和组织。 审判组织标本将用于微阵列制备和免疫组织化学。核心B，服务 作为GLP机构，将通过ELISPOT监测对接种疫苗的免疫应答 测定、四聚体分析或细胞因子流式细胞术（CFC）。上清液或体液中的细胞因子将被 通过IMCPL中建立的基于免疫珠的多重方法进行监测。核心B也将是 准备协助SPORE研究者实施免疫学评价所需的试验， 疫苗的反应，包括调节性T细胞（Treg）的表型和功能测定。核心 将确保其产生的所有细胞产品和收集的样本都附有适当的 允许将实验室分析与临床结果联系起来的文件。核心B还将提供 协助准备IND申请。核心实验室有着悠久的合作历史， 在拟定的临床和临床前研究背景下，所有SPORE研究者将 完全致力于支持为黑色素瘤或皮肤T细胞癌患者开发的疗法， 淋巴瘤（CTCL）。

Core B: Immunologic Monitoring and Cellular Products Laboratory/Tissue Microarray Core (IMCPL/TMA) This laboratory is a specialized facility at the University of Pittsburgh Cancer Institute (UPCI), which is dedicated to the state-of-the-art evaluation of immune responses prior to, during and after therapeutic interventions in patients with cancer. In addition to generating cellular products for human therapy, it also provides specialized morphology services. In its role as Core B for the SKIN SPORE, the IMCPL will assume responsibility for supporting the biotherapy-based clinical trials proposed by the projects. Core B, functioning as a GMP facility, will culture and characterize dendritic cells (DC) for patient therapy and prepare vaccines by pulsing these DC with peptides or proteins or infecting DC with AdV, as specified in the clinical protocols associated with the SPORE grant. Core B will be responsible for quality and sterility of the DC-based vaccines. It will also procure and process all body fluids and tissues harvested in the course of the clinical trials. Tissue specimens will be used for microarray preparation and immunohistochemistry. Core B, serving as a GLP facility, will monitor immunologic responses to the administered vaccines by performing ELISPOT assays, tetramer analyses or cytokine flow cytometry (CFC). Cytokines in supernatants or body fluids will be monitored by the immunobead-based multiplex method established in the IMCPL. Core B will also be prepared to assist the SPORE investigators in implementing assays necessary for evaluation of immunologic responses to vaccines, including phenotypic and functional assays for regulatory T cells (Treg). The Core will ensure that all cellular products it generates and samples it collects are accompanied by appropriate documentation that will permit linking laboratory analyses with clinical results. Core B will also provide assistsance in preparation of IND submissions. The Core laboratory has a long history of collaboration with all of the SPORE investigators, and in the context of the proposed clinical and pre-clinical studies will be entirely dedicated to the support of therapies being developed for patients with melanoma or cutaneous Tcell lymphoma (CTCL).